Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
107.67
(
-0.54%
)
Bitcoin
67,265.00
(
1.98%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 53129

Wednesday, 04/30/2008 3:54:46 PM

Wednesday, April 30, 2008 3:54:46 PM

Post# of 257302
VRUS admitted (on today’s MS webcast) that the data showing SVR potential for Clevudine in HBV is largely anecdotal.

I’ve long thought that VRUS has been overstating the case that Clevudine is unique among HBV nucleoside/nucleotide drugs in its ability to generate an SVR (#msg-23359068).

Comments?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today